Menu
Recruiting NCT06152497

The Role of Histamine in Muscle Protein Synthesis Following Resistance Training

No phase Interventional Histamine

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Placebo, H1 blockade: Telfast: 180mg Fexofenadine, Resistance training.
Who it may be relevant to
Registry conditions: Histamine. Basic parameters: 18 years — 45 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Belgium
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Role of Histamine in Muscle Protein Synthesis Following Chronic Resistance Training

Overview

Blocking histamine H1/H2 receptors blunts chronic endurance training adaptations. The current study addresses the following research question: "What is the influence of histamine H1 signaling on training adaptations following ten weeks of resistance training in human skeletal muscle." Results from this study will yield more insights into the molecular mechanisms of adaptations to exercise training.

Interventions

  • Drug Placebo
    Oral placebo
  • Drug H1 blockade: Telfast: 180mg Fexofenadine
    H1 blockade: oral blockade with 180mg Fexofenadine
  • Behavioral Resistance training
    Resistance training: lower body exercise

Primary outcome measures

  • Muscle volume [Time frame: Before and after the 10 weeks of resistance training]
  • Maximal dynamic strength of leg press, bench press, bicep curl and leg curl [Time frame: Before and after the 10 weeks of resistance training]
  • Muscle fiber hypertrophy in muscle biopsies [Time frame: Before and after the 10 weeks of resistance training]
  • Matsuda index, to estimate whole body glucose metabolism, will be calculated using an oral glucose tolerance test (OGTT: concentration of glucose and insulin in the blood will be measured before and after drinking 75g glucose) [Time frame: Before and after the 10 weeks of resistance training]
  • Vascular function measured with a single passive leg movement (sPLM: change in femoral blood flow measured with Doppler ultrasound before and after one passive flexion/extension of the leg) [Time frame: Before and after the 10 weeks of resistance training]
Secondary outcome measures (2)
  • Blood pressure (systolic and diastolic) [Time frame: Before and after the 10 weeks of resistance training]
  • Resting heart rate [Time frame: Before and after the 10 weeks of resistance training]

Eligibility criteria

Inclusion criteria

  • Male
  • 18-45 years
  • Not to medium physically active

Exclusion criteria

  • Smoking
  • Chronic disease
  • High blood pressure
  • Supplement or medication intake
  • Seasonal allergies
  • Vegetarian / vegan
  • Resistance trained

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Basic science

Study locations

Belgium · 1 center
  • Department of movement and sports sciences, Ghent University, Belgium — Ghent

Identifiers

NCT: NCT06152497 · MPSH - ONZ-2023-0027

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗